@entity3131 ( @entity15795 ) is a newly developed anti-fibrotic agent. We evaluated the effect of @entity15795 for the prevention of @entity8 using a spontaneous progressive @entity631 animal model, @entity33354 /Kist @entity19 . Male and female @entity33354 /Kist @entity19 were fed a diet containing 0.5% @entity15795 or the same control diet (CD) without @entity15795 , for 1, 2, or 3-month periods. Body weight was monitored for the general effect of @entity15795 on the @entity19 . @entity644 and glomerular filtration rate (GFR) were evaluated for renal function. The @entity1463 index was examined for the morphological changes. There were no significant changes in body weight between the @entity15795 and control groups in both sexes. @entity644 levels were low in all the @entity15795 groups compared to the corresponding CD groups. The @entity1463 scores were also reduced in both sexes of the 3-month @entity15795 groups (p<0.05), and glomerular filtration rates were increased in both sexes of the 3-month @entity15795 groups compared to the CD groups. The treatment of @entity15795 for 1 or 2-month periods did not have statistic significances but the treatment for 3 months had statistic significances in @entity1463 and GFR compared to CD groups. These results suggested that long-term administration of @entity15795 suppressed the progression of @entity631 and improved renal function of the @entity33354 /Kist @entity19 .

@entity3131 suppressed the development of @entity631 in the @entity33354 /Kist XXXX .

@entity644 :: ('MESH:D011507', 'Disease') :: ['Proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal fibrosis'] @entity15795 :: ('CHEBI:31263', 'Chemical') :: ['PFD'] @entity33354 :: ('MESH:C537923', 'Disease') :: ['FGS'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity3131 :: ('MESH:C093844', 'Chemical') :: ['Pirfenidone'] @entity1463 :: ('MESH:D012598', 'Disease') :: ['sclerosis'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulosclerosis']
@entity19 :: (10090,Species) :: ['mouse']
